Profile data is unavailable for this security.
About the company
WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)22.79bn
- Net income in HKD4.77bn
- Incorporated2014
- Employees12.55k
- LocationWuXi Biologics (Cayman) IncNo. 108, Meiliang Road, MashanWUXI ChinaCHN
- Websitehttps://www.wuxibiologics.com/
More ▼
Mergers & acquisitions
| Acquired company | 2269:HKG since announced | Transaction value |
|---|---|---|
| WuXi XDC Cayman Inc | 0.45% | 181.93m |
Data delayed at least 15 minutes, as of Mar 05 2026 05:34 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Insilico Medicine Cayman TopCo | 419.21m | -346.79m | 30.98bn | -- | -- | -- | -- | 73.91 | -0.6222 | -0.6222 | 0.752 | -9.56 | -- | -- | -- | -- | -- | -- | -- | -- | 83.56 | -- | -82.72 | -- | -- | -- | -- | -- | 67.71 | -- | 91.92 | -- | -- | -- |
| Shanghai Bao Pharmaceuticals Co Ltd | 53.02m | -432.11m | 50.33bn | -- | -- | 49.79 | -- | 949.22 | -1.33 | -1.33 | 0.1627 | 3.10 | -- | -- | -- | -- | -- | -- | -- | -- | 97.96 | -- | -814.93 | -- | 2.07 | -- | 0.2168 | -- | -11.11 | -- | -127.21 | -- | -- | -- |
| Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.71bn | -820.68m | 81.94bn | 1.87k | -- | 14.38 | -- | 48.05 | -3.66 | -3.66 | 7.56 | 24.44 | 0.3067 | 4.93 | 13.37 | 928,368.10 | -14.76 | -- | -17.11 | -- | 57.10 | -- | -48.12 | -- | 6.32 | -- | 0.0255 | -- | 25.48 | -- | 53.54 | -- | -- | -- |
| Akeso Inc | 2.85bn | -961.41m | 91.70bn | 3.53k | -- | 12.22 | -- | 32.14 | -1.09 | -1.09 | 3.26 | 8.15 | 0.2115 | 0.7726 | 3.95 | 940,109.90 | -7.07 | -8.38 | -8.20 | -9.82 | 79.26 | -- | -33.46 | -33.18 | 4.01 | -536.98 | 0.4168 | -- | -53.08 | 97.39 | -125.37 | -- | 34.14 | -- |
| WuXi Biologics (Cayman) Inc | 22.79bn | 4.77bn | 153.09bn | 12.55k | 32.93 | 2.95 | 20.25 | 6.72 | 1.12 | 1.12 | 5.44 | 12.55 | 0.3442 | 6.36 | 3.06 | 1,812,328.00 | 8.45 | 7.98 | 10.57 | 9.95 | 42.65 | 42.71 | 24.54 | 25.82 | 2.69 | -- | 0.0943 | 0.00 | 9.63 | 36.21 | -1.28 | 27.05 | 3.97 | -- |
Data as of Mar 05 2026. Currency figures normalised to WuXi Biologics (Cayman) Inc's reporting currency: Hong Kong Dollar HKD
15.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 135.50m | 3.28% |
| BlackRock Fund Advisorsas of 19 Feb 2026 | 102.64m | 2.48% |
| BlackRock Advisors (UK) Ltd.as of 19 Feb 2026 | 75.51m | 1.83% |
| Schroder Investment Management Ltd.as of 31 Jan 2026 | 59.39m | 1.44% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 57.97m | 1.40% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 53.64m | 1.30% |
| TIAA-CREF Investment Management LLCas of 31 Dec 2025 | 45.13m | 1.09% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 44.97m | 1.09% |
| Schroder Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 35.65m | 0.86% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 34.98m | 0.85% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
